伊立替康联合顺铂方案治疗小细胞癌临床观察

背景与目的:依托泊苷联合顺铂(EP)方案是小细胞癌(SCC)全身化疗的经典方案,但其疗效仍不理想.伊立替康(CPT-11)作为抗肿瘤新药已有报道用于SCC的治疗.本研究旨在评价CPT-11联合顺铂(DDP)方案治疗SCC的近期疗效及毒性反应.方法:2006年1月-2007年12月采用CPT-11联合顺铂(DDP)方案治疗SCC患者31例,CPT-11 60 mg/m2 加入0.9%氯化钠溶液250 ml中静脉滴注,第1、8、15天给药;DDP 25 mg/m2 加入0.9%的氯化钠溶液500 ml中静脉滴注,第1～3天给药,28 d为1周期;化疗2个周期后评价疗效.结果:全组31例患者均可评价疗效,其中CR 4例、PR 15例、SD 5例、PD 7例,近期有效率为61.3%,主要毒性反应包括骨髓抑制、恶心呕吐及迟发性腹泻.结论:CPT-11联合DDP方案治疗SCC疗效确切,毒性反应可以耐受,值得进一步深入研究.

Irinotecan plus cisplatin for the treatment of small cell lung carcinoma

Background and purpose: Etoposide plus cisplatin (EP) is a classical combination chemotherapy regimen for small cell carcinoma (SCC), but the effect remains far from satisfactory. As a new anticancer regimen, irinotecan(CPT-11) has been reported in the treatment of SCC. This trail is to evaluate the effi cacy and side effects of CPT-11 plus cisplatin(DDP) regimen in the treatment of patients with SCC. Methods:The patients with SCC were treated with CPT-11 plus DDP regimen. CPT-11 was given at 60 mg/m2 by intravenous infusion on days 1,8,15 and DDP was given at 25 mg/m2 by intravenous infusion on days 1-3. Treatment was repeated every 28 days and the effi cacy was evaluated after two cycles. Results:Thirty-one of all the cases could be evaluated. The objective response rate was 61.3%, and included 4 complete response, 15 partial response, 5 stable disease and 7 progressive disease. The main side effects were myelosuppression, nausea, vomiting and late-onset diarrhea. Conclusions:The combination of CPT-11 and DDP is effective with tolerable side effects in the treatment of SCC, but further investigation trails are to be needed.